![Alan Sebulsky](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alan Sebulsky
Directeur/Membre du Conseil chez
PARABILIS MEDICINES, INC.
Fortune : 1 M $ au 31/07/2026
Profil
Alan M.
Sebulsky is currently an Independent Director at Parabilis Medicines, Inc. since 2026.
Former roles include Director at Arrow International LLC, GMP Cos., Inc., LifeSync Holdings, Inc., Accumetrics, Inc., Bass Enterprises, Adage Capital Management LP, and Apothecary Capital LLC.
Served as Independent Director at Jazz Pharmaceuticals, Inc. from 2004 to 2012 and at Jazz Pharmaceuticals Plc in 2012.
Held Managing Director positions at Morgan Stanley & Co. LLC from 1988 to 1994, Lincoln Capital Management Co. from 1994 to 2002, and Neumeier Capital Management, Inc. from 1994 to 2002.
Was Vice President at T.
Rowe Price Associates, Inc. (IM) from 1982 to 1987.
Worked as Principal at Lehman Brothers Asset Management LLC from 1994 to 2000.
Education includes undergraduate and graduate degrees from the University of Wisconsin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/06/2026 | 30 000 ( 0,03% ) | 1 M $ | 31/07/2026 |
Postes actifs de Alan Sebulsky
| Sociétés | Poste | Début |
|---|---|---|
| PARABILIS MEDICINES, INC. | Directeur/Membre du Conseil | 01/05/2026 |
Anciens postes connus de Alan Sebulsky
| Sociétés | Poste | Fin |
|---|---|---|
| JAZZ PHARMACEUTICALS PLC | Directeur/Membre du Conseil | 01/07/2012 |
Jazz Pharmaceuticals, Inc.
 Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Directeur/Membre du Conseil | 01/01/2012 |
GMP Cos., Inc.
 GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals, diagnostic products, and medical devices | Directeur/Membre du Conseil | 01/12/2009 |
Lincoln Capital Management Co. | Corporate Officer/Principal | 01/01/2002 |
Neumeier Capital Management, Inc.
 Neumeier Capital Management, Inc. Investment ManagersFinance Provides investment advice | Corporate Officer/Principal | 01/01/2002 |
Formation de Alan Sebulsky
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
82
Relations au 1er degré
16
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 16 |
|---|---|
T. Rowe Price Associates, Inc. (IM)
 T. Rowe Price Associates, Inc. (IM) Investment ManagersFinance Price Associates uses a complex and multifaceted approach to investment analysis and asset management decisions. They integrate ESG factors into their investment research process. The firm focuses on the ESG factors they consider most likely to have a material impact on the performance of securities in client accounts. Price Associates also focuses on their analytical process on three areas of research: the industry, the contracts issued, and the creditworthiness of each individual issuer. | Finance |
Arrow International LLC
 Arrow International LLC Medical SpecialtiesHealth Technology Develops, manufactures and markets disposable catheters & related products for critical and cardiac care | Health Technology |
Bass Enterprises
 Bass Enterprises Investment ManagersFinance Bass Enterprises employs a multi-strategy market neutral approach that includes merger, volatility and convertible arbitrage. The firm uses top-down, quantitative and qualitative analysis in their stock selection process. | Finance |
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals, diagnostic products, and medical devices | Health Technology |
Adage Capital Management LP
 Adage Capital Management LP Investment ManagersFinance Adage manages ACP primarily through industry-specific portfolios that are managed by analyst/portfolio manager teams or individuals. The ACP aims to provide investors with compound annual long-term returns that outperform the returns of the S&P 500 Index. Their analysts focus on adding value by stock selection based on intra-industry fundamental analysis. In addition to taking long positions, the firm uses leverage, sells securities short, and invests in derivatives, US and non-US equities and private securities. | Finance |
Lehman Brothers Asset Management LLC
 Lehman Brothers Asset Management LLC Investment Banks/BrokersFinance For active fixed-income, LBAM's decision-making process incorporates controlled duration decisions, sector decisions, and individual issue valuation decisions. They base interest rate and sector-related investment decisions on our economic growth forecast. The firm uses risk exposure analysis and risk budgeting models to quantify and manage risks associated with strategies that they design to add value relative to the benchmark index. Individual issue selections result from internal research generated by research specialists. They diversify holdings to reduce credit exposure to individual issuers. Eligible investments for core strategies include US dollar denominated investment-grade securities; for core plus strategies the universe of securities expands to include high yield. For passive bond indexing, LBAM seeks to take advantage of risk premiums as they are reflected in individual security prices. These premiums offer compensation for accepting credit and structure risks associated with individual issues. Explicit quantification and control of risks are at the heart of this investment process. The firm uses proprietary risk exposure analysis to analyze yield curve factors and spread-related factors. For each yield curve and spread factor, the portfolio is very closely matched to the index to ensure that the portfolio earns the same return as the index for any change in interest rates or change in sector spreads. Based on internally generated research, they integrate individual issue selections into the portfolio without disrupting the integrity of the portfolio structure. Holdings are diversified to reduce credit exposure to individual issuers. Eligible investments include securities included in the index, plus those that are their equivalents in terms of credit and structure risks. LBAM's high yield bond management decision-making process begins with a macro-economic framework for determining the appropriate portfolio structure according to defensive versus cyclical industries and appropriate quality orientation (between high BB to low B). Once they have established the overall structure, the firm determines specific industry weights and individual issuer selections. Their research analysts focus on identifying securities that exhibit improving credit fundamentals while avoiding those that experience deterioration in their credit quality. LBAM diversifies holdings to reduce credit exposure to individual issuers. Eligible investments include dollar denominated bonds rated below investment-grade including Rule 144A securities and the full range of structures such as pay-in-kind bonds, interest reset bonds and other instruments that are consistent with high yield investing. | Finance |
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Health Technology |
LifeSync Holdings, Inc.
 LifeSync Holdings, Inc. Medical SpecialtiesHealth Technology Operates as a holding company with interest in medical devices | Health Technology |
Morgan Stanley & Co. LLC
 Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Accumetrics, Inc.
 Accumetrics, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and markets diagnostic testing and measurement instruments | Health Technology |
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Apothecary Capital LLC
 Apothecary Capital LLC Investment ManagersFinance Apothecary Capital focuses on investments in the healthcare sector | Finance |
Lincoln Capital Management Co. | |
Jazz Pharmaceuticals Plc
 Jazz Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of pharmaceutical products to treat neurological disorders | Health Technology |
Neumeier Capital Management, Inc.
Neumeier Capital Management, Inc. Investment ManagersFinance Provides investment advice | Finance |
Parabilis Medicines
 Parabilis Medicines Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for cancers and tumors | Health Technology |
